B-cell non-Hodgkin's lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting oncogenes and tumour-suppressor genes. We report here that the two most common types-follicular lymphoma and diffuse large B-cell lymphoma-harbour frequent structural alterations inactivating CREBBP and, more rarely, EP300, two highly related histone and non-histone acetyltransferases (HATs) that act as transcriptional co-activators in multiple signalling pathways. Overall, about 39% of diffuse large B-cell lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or somatic mutations that remove or inactivate the HAT coding domain of these two genes. These lesions usually affect one allele, suggesting that reduction in HAT dosage is important for lymphomagenesis. We demonstrate specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 tumour suppressor. These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin's lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.
Diffuse large B-cell lymphoma (DLBCL) represents the most common form of B-cell non-Hodgkin lymphoma (B-NHL), accounting for about 30% of new diagnoses and also arising as a frequent clinical evolution of follicular lymphoma 1 . The molecular pathogenesis of DLBCL is associated with multiple genetic lesions that segregate in part with individual phenotypic subtypes, namely germinal-centre B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL, suggesting the involvement of distinct oncogenic pathways [2] [3] [4] [5] [6] [7] [8] . However, the full spectrum of lesions that contribute to malignant transformation remains unknown. Genome-wide efforts toward the identification and functional characterization of the entire set of structural alterations present in the DLBCL genome are required for a complete understanding of its pathogenesis 9 .
Towards this end, we have integrated next-generation wholeexome sequencing analysis of seven DLBCL cases and genome-wide high-density single nucleotide polymorphism (SNP) array analysis of 72 DLBCL cases. This combined approach led to the identification of over 450 loci that are affected by somatic point mutations and/or by recurrent, focal gene copy number aberrations. Among those that have been independently validated, the most commonly involved regions were those harbouring the acetyltransferase genes CREBBP (CBP) and EP300 (p300). CREBBP encodes a highly conserved and ubiquitously expressed nuclear phosphoprotein that, together with the closely related protein EP300, belongs to the KAT3 family of histone/protein lysine acetyltransferases 10, 11 . CREBBP and EP300 function as transcriptional coactivators for a large number of DNAbinding transcription factors involved in multiple signalling and developmental pathways, by modifying lysine residues on both histone and non-histone nuclear proteins 12, 13 .
CREBBP and EP300 enhance transcription by multiple mechanisms, including: (1) targeted acetylation of chromatin 12, 13 ; (2) acetylation of transcriptional activators (such as the tumour suppressors p53 and GATA1) [14] [15] [16] [17] ; and (3) acetylation-mediated inactivation of transcriptional repressors (such as the DLBCL-associated oncogene BCL6) 18 . Additionally, both molecules were found to exhibit ubiquitin ligase activity 19, 20 . Consistent with the involvement in critical cellular functions, homozygous null mice for either Crebbp or Ep300 are early embryonic lethal 21, 22 , and the same is true for compound Crebbp/ Ep300 double heterozygous mice 21, 22 . Haploinsufficiency of CREBBP (and, rarely, EP300) is responsible for Rubinstein-Taybi syndrome, an autosomal congenital disorder characterized by mental and growth retardation, skeletal abnormalities and predisposition to tumour development [23] [24] [25] . Somatic mutations of these two genes are exceedingly rare in epithelial cancers [26] [27] [28] , and only three cases were reported to carry EP300, but not CREBBP mutations in haematologic malignancies 29, 30 . Additionally, chromosomal translocations of CREBBP are associated with an infrequent type of acute myeloid leukaemia and with therapy-related acute myeloid leukaemia and myelodysplastic syndrome, although the precise consequences of these lesions have not been fully elucidated [31] [32] [33] .
Monoallelic lesions of CREBBP in DLBCL
Following initial observations from whole-exome sequencing analysis of seven DLBCL cases and paired normal DNAs, we performed targeted re-sequencing of the entire CREBBP coding exons in 134 DLBCL samples representative of major phenotypic subtypes. This analysis revealed a total of 34 sequence variants distributed over 30 samples and the somatic origin of which was documented by analysis of paired normal DNAs (available in eight cases)( Fig. 1a and b, and Supplementary Table 1 ). Of these variants, 17 (50%) were inactivating events, including nonsense mutations (n 5 9), frameshift insertions/deletions (n 5 7) and mutations at consensus splice donor/splice acceptor sites (n 5 1), which generate aberrant transcripts carrying premature stop codons. On the basis of their distribution along the CREBBP protein, these mutations are all predicted to cause the elimination or truncation of the HAT domain ( Fig. 1a and Supplementary Table 1 ). The remaining variants included three in-frame deletions and 14 missense mutations, primarily within the HAT domain ( Fig. 1a and Supplementary  Table 1 ), suggesting that they may be functionally important (see below). Although CREBBP mutations were identified in both DLBCL phenotypic subtypes, their frequency was significantly higher in GCB-DLBCL, where they account for about 32% of the cases (n 5 21/65) as compared to 13% in ABC/non-classified (NC) DLBCL (n 5 9/69; P , 0.01) ( Fig. 1c ).
High-density SNP array analysis, available for 72 samples from the same panel, and fluorescence in situ hybridization (FISH) analysis revealed the presence of monoallelic deletions encompassing or internal to the CREBBP locus in eight additional cases (five GCB-DLBCL and three ABC/non-GC-DLBCL), and a homozygous deletion in one patient ( Fig. 2a and b, and Supplementary Fig. 1 ). Notably, the loss of genetic material was smaller than 240 kilobases (kb) in four cases and, in two patients (2147 and 2043), involved only a limited subset of CREBBP exons, thereby identifying this gene as the specific target ( Fig. 2a and Supplementary Table 2 ). In two additional samples for which copy number data were not available, direct sequencing analysis revealed a hemizygous missense mutation, reflecting either the loss of the second allele or copy neutral loss of heterozygosity (Supplementary Table 1 ). When combining the sequencing data with the copy number data, CREBBP mutations and deletions were found to be mutually exclusive in most samples, revealing a predominantly monoallelic distribution (n 5 33/39 cases) ( Fig. 2c ). Rare instances of biallelic genetic lesions include the homozygous loss, a missense mutation with loss of heterozygosity (two primary biopsies), biallelic nucleotide substitutions (two cases), and a frameshift deletion with missense mutation of the second allele in the OCI-Ly8 cell line. Thus, 29% of all DLBCL patients (n 5 39/134), corresponding to 41.5% of GCB-DLBCL and 17% of ABC-DLBCL, harbour genomic alterations affecting the CREBBP gene ( Fig. 2d ).
Frequent mutations of CREBBP in follicular lymphoma
We next analysed various types of mature B-NHL, including follicular lymphoma, Burkitt lymphoma, marginal-zone lymphoma and chronic lymphocytic leukaemia. Mutations analogous to those found in DLBCL were frequent in follicular lymphoma (32.6%, with 16 events distributed over 15/46 cases), but not in other lymphoma types, suggesting a specific role in the pathogenesis of these two diseases ( Supplementary Fig. 2 ). This analysis also revealed the existence of several mutational hotspots at specific codons within the HAT domain, including R1446 (also mutated in B-cell acute lymphoblastic leukaemia 34 ), Y1503 and D1435; in addition, a 3-base-pair (bp) inframe deletion causing the loss of S1680 was observed in five cases, suggesting a functional role for this currently uncharacterized serine (Supplementary Table 1 ). None of these recurrent changes was detected in paired normal DNA, indicating that they do not represent germline polymorphisms. Although copy number data were not available for the same follicular lymphoma panel, array-CGH analysis performed on a distinct data set showed deletions spanning the CREBBP locus in only 1/68 cases (not shown). Collectively, these findings identify somatic mutations of CREBBP as a common event in follicular lymphoma. 
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Given the significant structural and functional similarities between CREBBP and EP300, we investigated whether this second member of the KAT3 acetyltransferase family is also targeted by structural alterations in B-NHL. Mutational analysis of the same panel identified 19 sequence variants leading to amino acid changes (n 5 11), in-frame deletions (n 5 2), and premature stop codons due to frameshift deletions, aberrant splicing or nonsense mutations (n 5 6) (Supplementary Fig. 3a and Supplementary Table 3 ). These lesions were found in 10% of DLBCL (n 5 13/134) and 8.7% of follicular lymphoma samples (n 5 4/46), but were almost absent in other B-NHLs ( Supplementary  Fig. 3b ). Seven additional DLBCLs harboured monoallelic deletions spanning, although not limited to, the EP300 locus ( Supplementary  Fig. 3c , Supplementary Table 4 and data not shown). Notably, structural alterations of CREBBP and EP300 coexist in only a minority of the affected cases (n 5 6/53 DLBCL and 0/19 follicular lymphoma) (Supplementary Fig. 3d ), suggesting that inactivation of these loci is at least in part functionally equivalent. Thus, overall about 39% of all DLBCL and at least 41% of follicular lymphoma cases (based on mutations only) display structural alterations of KAT3 family genes.
CREBBP and EP300 protein expression
To compare the CREBBP and EP300 protein levels in normal and transformed B cells, and to investigate the expression of the retained normal allele in cases carrying monoallelic genomic alterations, we examined the expression pattern of these two proteins in reactive human tonsils and in 78 DLBCL primary cases, of which 49 harboured both genes in wild-type configuration, using immunofluorescence and immunohistochemical analysis. Consistent with their reported ubiquitous expression, CREBBP and EP300 were detectable in naive B cells within the mantle zone and, at higher levels, in germinal-centre B cells (Fig 3a) . Notably, most of the monoallelically deleted DLBCL cases were positive for the two proteins, although at reduced levels, demonstrating that the residual wild-type allele is expressed (see Fig. 3b and c for representative examples). Furthermore, reverse-transcription polymerase chain reaction (RT-PCR) amplification and direct sequencing of the ten CREBBP-mutated cell lines invariably showed the presence of the wild-type allele ( Supplementary Fig. 4 ), while western blot analysis using antibodies directed against the amino-terminal portion of CREBBP revealed the expression of a full-length protein, corresponding to the wild-type allele, in most of the cell lines carrying truncating gene mutations, as well as in the monoallelically deleted SUDHL5 cells (Fig. 3d , top panel). Slightly different findings were observed for EP300, where the presence of truncating mutations or deletions was associated with the absence of protein expression in four affected cell lines ( Fig. 3d , second panel from top). With the exception of SUDHL2, both CREBBP and EP300 messenger RNAs were readily detected by northern blot analysis in all lines analysed (Fig 3d, panels 4 and 5 from top).
Interestingly, a few additional lines were found to express very low or undetectable protein levels, despite the presence of mRNA and the absence of structural alterations in the corresponding gene (see CREBBP in BJAB and SUHDL2, or EP300 in SUDHL7) ( Fig. 3d) . Similarly, 6/78 (8%) DLBCL biopsies from patients with intact alleles appeared to lack expression of the two proteins, either simultaneously (three cases) or individually (two CREBBP1/EP3002 cases and one CREBBP2/EP300 1 case) ( Fig. 3c and e ). Thus, the fraction of DLBCL patients with defective CREBBP and EP300 may be higher than that determined on the basis of genetic lesions alone, suggesting that alternative mechanisms of KAT3 gene family inactivation may have a role in this disease. 
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CREBBP missense mutants fail to acetylate BCL6 and p53
The presence of gross gene deletions and the distribution of truncating mutations clearly predict a complete gene inactivation or the loss of multiple key functional domains, including the HAT; on the contrary, the functional consequences of the numerous CREBBP missense mutations required direct experimental analysis. Notably, of the 30 total events identified, 27 cluster within HAT coding exons, suggesting a selective pressure to alter the CREBBP enzymatic activity (Supplementary Table 1 ). In particular, 19 mutations were located within a 68amino-acid stretch that is 96% identical to EP300 and includes the contact surface for coenzyme A (CoA) 35 ( Supplementary Fig. 5 ). We therefore examined the effect of these mutations on the ability of CREBBP to acetylate known physiologic substrates. We selected BCL6 and p53 because of their biological relevance for germinalcentre development and lymphomagenesis 4, 36 . In fact, acetylation of the tumour suppressor p53 is indispensable for its transcriptional activity 14, 15, 37 , whereas EP300-mediated acetylation of the protooncoprotein BCL6 leads to inactivation of its transcriptional repressor function 18 . Transient transfection/co-immunoprecipitation assays confirmed that, analogous to EP300 18 , CREBBP binds to and acetylates BCL6, leading to a dose-dependent impairment in its ability to repress a BCL6-responsive reporter gene ( Supplementary Fig. 6a and b ). We then generated haemagglutinin (HA)-tagged constructs for expression of nine representative CREBBP alleles harbouring missense mutations within (n 5 6) or immediately outside (n 5 2) the core HAT domain, as well as a premature stop codon (R1360X) (Fig. 4a) . Notably, all of the HAT domain mutant proteins had lost their ability to acetylate BCL6 ( Fig. 4b ) and to interfere with its transrepression activity, consistent with the reported role of acetylation in inactivating BCL6 (Fig 4c) . Conversely, no significant effects were observed from the C1240R and K1320R proteins or from two additional alleles (P1053L, Q1079H) harbouring mutations outside the HAT domain (Supplementary Table 1 and data not shown), although C1240R appeared to have lost its activity in the reporter assay, suggesting that alternative mechanisms may be involved.
When tested on the tumour suppressor p53, the same core HAT mutants were either impaired or severely attenuated (H1487Y and D1435E) in their acetylation activity, as compared to wild-type CREBBP or to C1240R and K1320R (Fig. 4d ). It should be noted that C1240R and K1320R represent a second mutational event in cases carrying an additional truncating CREBBP mutation (see Supplementary Table 1 ), suggesting the possibility that they represent passenger events or that they confer more subtle functional consequences. Taken together, these findings demonstrate that CREBBP missense mutant alleles have been selected for their defective HAT activity. In particular, the impairment on BCL6 and p53 acetylation is consistent with specific effects of CREBBP genetic lesions in favouring the constitutive activity of the BCL6 oncogene over the function of the p53 tumour suppressor.
CREBBP mutations reduce affinity for acetyl-CoA binding
To investigate the mechanisms responsible for the observed loss of function on BCL6 and p53, we examined the effect of CREBBP mutations on subcellular localization, enzyme-substrate complex formation, and enzymatic activity. All mutants tested were correctly localized in 
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the nuclear compartment and could be efficiently co-immunoprecipitated with BCL6 or p53 ( Supplementary Fig. 7 and data not shown), indicating that the inability to acetylate these substrates in vivo was not due to mislocalization or to impaired physical interaction. Instead, in vitro acetylation assays using recombinant glutathione S-transferase (GST)-p53 and highly purified, wild-type or mutated CREBBP proteins demonstrated a marked, acetyl-CoA dose-dependent defect in the enzymatic activity of the core HAT mutants ( Fig. 5 and Supplementary Fig. 8 ), suggesting that these changes impair the affinity for acetyl-CoA (see also Supplementary Fig. 5 ).
CREBBP mutants are biologically inactive
To further investigate the consequences of CREBBP missense mutations on its function as a transcriptional co-activator, we examined the response of endogenous 39,59-cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) target genes in mouse embryonic fibroblasts (MEFs) carrying conditional Crebbp and Ep300 double knockout alleles, reconstituted with retroviral vectors expressing either wild-type or DLBCL-associated mutant Crebbp complementary DNAs ( Supplementary Fig. 9a ), and treated with forskolin and IBMX (two inducers of Protein Kinase A activity). In normal cells, Protein Kinase A-mediated phosphorylation of CREB is required for the recruitment of CREBBP, which in turn leads to transcriptional activation of cAMP-responsive genes 38 . As previously observed 39 , quantitative RT-PCR analysis of CREBBP/EP300-dependent CREB target genes confirmed their upregulation in doubleknockout cells reconstituted with wild-type CREBBP expression constructs ( Supplementary Fig. S9b, column 2 from left) . In contrast, all four DLBCL-derived CREBBP mutants tested were generally deficient for cAMP-responsive transcription, as was the HAT-dead control W1502A/Y1503S 40 (Supplementary Figs 9b and 10) . These mutants were also associated with reduced endogenous histone H3K18 acetylation ( Supplementary Fig. 11 ). Finally, we tested whether the mutant CREBBP polypeptides were proficient in rescuing the proliferative defect of the double-knockout cells, given that this system provides a specific readout for the biological activity of the CREBBP point mutants. Notably, cells transduced with the four DLBCL-associated alleles displayed significantly impaired cell growth compared to wildtype reconstituted cells, as measured in the yellow fluorescent protein (YFP) 1 (double-knockout) population ( Supplementary Fig. 9c ). Collectively, the data presented above provide direct experimental evidence for a role of HAT missense mutations in impairing the acetyltransferase activity of CREBBP and its function as a transcriptional coactivator.
Discussion
These results indicate that inactivation of CREBBP/EP300 represents a common event in the two most frequent forms of B-NHL, namely follicular lymphoma and DLBCL. Previous extensive surveys in malignancies of epithelial origin have reported inactivating mutations of EP300 and CREBBP in exceedingly rare cases (,2% of primary biopsies) [26] [27] [28] . Considering their almost total absence in solid tumours, and the finding of recurrent mutations in B-cell acute lymphoblastic leukaemia 34 , our results point to a specific role for CREBBP/EP300 inactivation in the pathogenesis of malignancies derived from B-lymphocytes. Overall, CREBBP/EP300 lesions are among the most frequent structural alterations yet detected in follicular lymphoma and DLBCL, thus representing an important feature of the pathogenesis 
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of these common diseases. Moreover, the observation of significantly reduced CREBBP and EP300 expression levels in a sizeable fraction of DLBCL samples, independent of genetic lesions ( Fig. 3e and Supplementary Fig. 12 ), suggests that additional epigenetic mechanisms may cause reduction of HAT dosage in a larger fraction of tumours.
One key observation of this study is that CREBBP/EP300 lesions are mostly detected in heterozygosity, suggesting a haploinsufficent role in tumour suppression. This notion is supported by several observations. First, congenital heterozygous mutations of CREBBP/EP300 are sufficient to cause significant pathologic and developmental phenotypes, including tumorigenesis, in patients with Rubinstein-Taybi syndrome [23] [24] [25] , thereby confirming the deleterious effect of reduced HAT activity. Second, a fraction of mice with conditional deletion of Crebbp in mature B cells showed reduced survival past 12 months of age 41 . Haematologic malignancies were also reported in 22% of constitutive 10-21-month-old Crebbp heterozygous mice and about 30% of chimeric animals after bone marrow or spleen cell transplantation from Crebbp heterozygotes 42 . Third, in contrast with the abundantly expressed histone deacetylases, HATs are limiting in the cell, suggesting that small dosage variations can have severe biological consequences 43 . Overall, these data provide direct evidence that CREBBP (and, more rarely, EP300) are haploinsufficient tumour suppressors, the specific roles of which in lymphomagenesis will have to be tested by conditional deletion of these alleles in germinal-centre B cells.
Given the global involvement of CREBBP/EP300 on gene transcriptional regulation, it is difficult to predict which cellular targets/ pathways may be critically affected by HAT reduction in lymphomagenesis. At this stage, our results demonstrate that mutant CREBBP and EP300 proteins are deficient in acetylating BCL6 and p53, leading to constitutive activation of the oncoprotein and to decreased p53 tumour suppressor activity. The balance between the activities of these two genes is critical for the regulation of DNA damage responses in mature germinal-centre cells during immunoglobulin gene remodelling 36, 44 . Thus, the consequences of BCL6 activity overriding p53 would be an increased tolerance for DNA damage in the context of diminished apoptotic and cell cycle arrest responses.
These results have important therapeutic implications in view of current attempts to use a variety of histone deacetylase inhibitors as anti-cancer drugs. Although the benefits of these compounds have been proved in certain malignancies, such as mature T-cell lymphoproliferative disorders, their efficacy in other common cancers, including B-NHL, is uncertain at this stage 45 . The findings of this study suggest that the use of histone deacetylase inhibitors has a rational basis in B-NHL, because it may contribute to re-establishing physiologic acetylation levels. On the other hand, their efficacy should be re-evaluated by stratifying patients based on the presence of HAT defects as well as by testing the numerous histone deacetylase and sirtuin inhibitors with target specificity.
METHODS SUMMARY
Mutation analysis. The complete coding sequences and exon/intron junctions of CREBBP and EP300 were analysed by PCR amplification and direct sequencing of whole-genome amplified DNA using the oligonucleotides reported in Supplementary Tables 5 and 6 . Mutations were confirmed from both strands on independent PCR products amplified from genomic DNA, and their somatic origin was documented by analysis of matched normal DNA in available cases. SNP array analysis. This was performed using Affymetrix Genome-Wide 6.0 Arrays and a computational workflow, which is described in detail in the Supplementary Information. In vivo and in vitro characterization of HAT activity. The ability of CREBBP mutants to acetylate BCL6 and p53 was assessed in human embryonic kidney (HEK293T) cells after co-transfection of pCMV-Flag-BCL6 (or pCIN4-Flag-p53) with plasmids encoding wild-type versus mutant HA-tagged mouse Crebbp. BCL6 acetylation was evaluated on Flag/M2 immunoprecipitates using antibodies directed against acetyl lysines; for p53, western blot analysis was performed on whole-cell extracts using a specific anti-acetylated p53 antibody. The amounts of exogenous CREBBP were monitored using anti-HA and anti-CREBBP (A22, Santa Cruz Biotechnology) antibodies. In vitro acetylation assays were performed using recombinant GST-p53 and purified CREBBP-HA proteins, in the presence of the indicated amounts of acetyl-CoA. Transient transfection/reporter gene assays. The effect of CREBBP on BCL6dependent transcription was assessed in HEK293T cells co-transfected with a luciferase reporter vector containing five BCL6 consensus binding sites upstream of the SV40 promoter (5XBCL6) and the pCMV-Flag-BCL6 construct, in the absence or presence of wild-type versus mutant CREBBP-HA expression vectors (see the online-only Methods). Reconstitution of Crebbp/Ep300 null MEFs. Crebbp flox/flox ;Ep300 flox/flox ;YFP 1 conditional (double knockout) MEFs have been described 39 . CREBBP expression was restored by retroviral infection with constructs encoding for HA-tagged wildtype or mutant Crebbp, and cells were analysed for H3K18 acetylation, cAMPdependent transcriptional responses and cell proliferation (see the online-only Methods). 
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